Skip to main content

Lupin launches Ipratropium Bromide Nasal Solution (Nasal Spray) in the United States

 
Lupin launches Ipratropium Bromide Nasal Solution in the United States

Global pharma major Lupin Limited announced the launch of Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in the United States. Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent® Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals, Inc. 

Ipratropium Bromide Nasal Solution (Nasal Spray) 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. Ipratropium Bromide Nasal Solution (Nasal Spray) 0.06% is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children aged 5 years and older. 

Ipratropium Bromide Nasal Solution (RLD Atrovent®) had estimated annual sales of USD 63 million in the U.S. (IQVIA MAT May 2025).